CTRI/2019/02/017481尚未招募未知
TRIHEXYPHENIDYL FOR TREATMENT OF DYSTONIA IN CHILDREN WITH CEREBRAL PALSY: A RANDOMIZED PLACEBO CONTROLLED TRIAL.
Abhishek S0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Residents of Delhi NCR
排除标准
- •1.Children who have received Trihexyphenidyl, any other anti-cholinergic or levodopa in last 3 months.
- •2.Children who have required titration in their baclofen dosage in last 3 months.
- •3.Poorly controlled epilepsy.
- •4.Diagnosed cases of Glaucoma or Congenital Heart block.
- •5.History of allergy or adverse reaction to anti-cholinergic drugs in the past.
- •6.History of orthopedic surgery or botulinum injection in last 6 months.
- •7.Presence of features of contractures or hip dislocation.
研究者
相似试验
尚未招募
1 期
Effectiveness of the drug Trihexyphenidyl for abnormal movements in children with Cerebral PalsyCTRI/2018/01/011571Maulana Azad Medical College
已完成
2 期
Childhood Hypertonia of Central Origin: A Trial of Anticholinergic Treatment EffectsDystoniaNCT00122044University of Southern California35
招募中
1 期
Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral PalsyPediatric DisorderGenetic PredispositionDystonia, SecondaryCerebral Palsy, Dystonic-RigidCerebral Palsy, DyskineticTrihexyphenidyl Adverse ReactionPharmacogenomic Drug InteractionDystoniaNCT06554288Children's Mercy Hospital Kansas City40
尚未招募
不适用
Outcome of treatment with Triheptanoin in pediatric patients with long chain fatty acid oxidation disorders (LCFAODs)longchain fatty acid oxidation disorders (LCFAODs)longchain fatty acid oxidation disorders (LCFAODs), outcome, treatmentTCTR20210604002/A2
已完成
3 期
Addition of Pyridoxine to Prednisolone in Infantile SpasmsInfantile SpasmsNCT01828437Lady Hardinge Medical College62